866-997-4948(US-Canada Toll Free)

Ewing Sarcoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 59 Pages


Global Markets Directs, \'Ewing Sarcoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ewing Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ewing Sarcoma. 

Ewing Sarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Ewing Sarcoma.
  • A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ewing Sarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ewing Sarcoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Ewing Sarcoma 8
Ewing Sarcoma Therapeutics under Development by Companies 10
Ewing Sarcoma Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Ewing Sarcoma Therapeutics - Products under Development by Companies 15
Ewing Sarcoma Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Ewing Sarcoma Therapeutics Development 17
Amgen Inc. 17
Eli Lilly and Company 18
Merck & Co., Inc. 19
Oncolytics Biotech Inc. 20
PharmaMar, S.A. 21
Ewing Sarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
cixutumumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ganitumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Reolysin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
robatumumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PM-00104 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
irinotecan hydrochloride + sorafenib tosylate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Reolysin + [cisplatin] + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tumor Cell B Lymphoblastoid Cell Line Vaccine + [aldesleukin] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Docetaxel + Gemcitabine + Filgrastim + Pegfilgrastim - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Autologous Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
E7 Peptide + [aldesleukin] + Autologous T Cell Transplantation - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
olaparib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
aldesleukin Aerosol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LSD-1 Inhibitor - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Ewing Sarcoma Therapeutics - Drug Profile Updates 49
Ewing Sarcoma Therapeutics - Discontinued Products 53
Ewing Sarcoma Therapeutics - Dormant Products 54
Ewing Sarcoma - Product Development Milestones 55
Featured News & Press Releases 55
Mar 31, 2012: Researchers State Combination Of Two Targeted Therapies Act Against Ewing\'s Sarcoma Tumors 55
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 56

Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Table


Number of Products Under Development for Ewing Sarcoma, H1 2013 8
Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Amgen Inc., H1 2013 17
Eli Lilly and Company, H1 2013 18
Merck & Co., Inc., H1 2013 19
Oncolytics Biotech Inc., H1 2013 20
PharmaMar, S.A., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Ewing Sarcoma Therapeutics - Drug Profile Updates 49
Ewing Sarcoma Therapeutics - Discontinued Products 53
Ewing Sarcoma Therapeutics - Dormant Products 54

List of Chart


Number of Products under Development for Ewing Sarcoma, H1 2013 8
Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *